This fact sheet describes a PATH project in Vietnam that is focusing on testing a new formulation of a locally made rotavirus vaccine. PATH, Vietnam-based manufacturer POLYVAC (Center for Research and Production of Vaccines and Biologicals), and Vietnam’s National Institute of Hygiene and Epidemiology are conducting a Phase 3 bridging study to compare a second-generation formulation of POLYVAC’s new liquid rotavirus vaccine (ROTAVIN) with the currently licensed version (ROTAVIN-M1). Both contain the same rotavirus strain, but ROTAVIN is stored at 2-8°C, while ROTAVIN-M1 must be kept frozen. ROTAVIN would therefore be more compatible with the cold chain currently in place in Vietnam, allowing for easier storage and transport. In the future, it could also be more attractive for use in other low- to middle-income settings.

Read the fact sheet in English

Read the fact sheet in Vietnamese